首页 › 肺癌 › 密歇根州

密歇根州的肺癌临床试验

密歇根州有 45 项针对肺癌的研究正在招募参与者。

密歇根州的城市

官方研究文本（英文）

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Local Institution - 0418, Ann Arbor
Local Institution - 0405, Detroit
Local Institution - 0420, Traverse City

招募中2/3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月13日 · NCT07063745

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Corewell Health - Butterworth Hospital, Grand Rapids
Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
Corewell Health - Research Specimen Processing Area, Grand Rapids
以及另外 2 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06758401

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

University of Michigan Rogel Cancer Center, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
以及另外 38 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
以及另外 49 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT04267848

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
以及另外 21 项

招募中3 期

70 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06096844

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

University of Michigan, Ann Arbor

招募中1/2 期

18 岁及以上 · 所有性别 · 更新于 2026年11月10日 · NCT07020221

The Vanguard Study: Testing a New Way to Screen for Cancer

Henry Ford Cancer Institute-Downriver, Brownstown
Henry Ford Health Center - Brownstown, Brownstown
Henry Ford Health Center - Chesterfield, Chesterfield
以及另外 13 项

招募中欢迎健康志愿者

45 至 75 岁 · 所有性别 · 更新于 2026年11月6日 · NCT06995898

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Henry Ford Cancer Institute, Detroit

招募中1/2 期

18 岁及以上 · 所有性别 · 更新于 2026年11月6日 · NCT04198766

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Profound Research, LLC, Farmington Hills

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月5日 · NCT06793215

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
以及另外 71 项

招募中观察性研究欢迎健康志愿者

40 至 75 岁 · 所有性别 · 更新于 2026年11月4日 · NCT05334069

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health Medical Center - Brighton, Brighton
以及另外 27 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT04181060

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT06400472

A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0119, Ann Arbor

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT07492680

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

University of Michigan, Ann Arbor
The Cancer & Hematology Centers, Grand Rapids

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT06119581

A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

START Midwest, LLC, Grand Rapids

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT07903415

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Henry Ford Cancer Institute, Detroit

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月2日 · NCT07185997

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

University of Michigan, Ann Arbor

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年11月2日 · NCT07499674

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

招募中

18 岁及以上 · 所有性别 · 更新于 2026年10月23日 · NCT02984761

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Karmanos Cancer Institute, Detroit

招募中1/2 期

18 岁及以上 · 所有性别 · 更新于 2026年10月19日 · NCT06244771

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
以及另外 4 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT07393555

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

招募中1/2 期

18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Karmanos Cancer Institiute, Detroit

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT06293898

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Profound Research LLC at Michigan Hematology and Oncology Consultants, Dearborn
Henry Ford Health System, Detroit

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT07128199

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health Medical Center - Brighton, Brighton
以及另外 14 项

招募中2 期

18 Minutes · 所有性别 · 更新于 2026年10月9日 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
以及另外 7 项

招募中2/3 期

18 岁及以上 · 所有性别 · 更新于 2026年10月9日 · NCT06616584